Why Mirum Pharmaceuticals (MIRM) Is Down 6.4% After Raising 2026 Sales Outlook Amid Wider Losses – And What's Next

EarningsNegative

AI Analysis

Summary

Mirum Pharmaceuticals raised its 2026 sales outlook but experienced a 6.4% stock decline despite the increased guidance, amid reports of wider losses.

Financial Highlights

Guidance

2026 sales outlook raised

Importance:4/10

Sentiment:

-0.30

earningsguidancestock_declinefinancial_results

Related Companies

$MIRM

Read the original article

Published by yahoo_finance on August 13, 2026 5:12 PM

Read Original